COMPANY

Alphyn Biologics

HQ: Annapolis, MD source · alphynbiologics.com ↗ · Mid-Atlantic

ALPHYN BIOLOGICS is developing therapies to treat the world’s most challenging, severe, and common skin diseases. From company website Source · Oct 12, 2026

Keywords: Atopic Dermatitis Atopic Dermatitis (Eczema) Atopic Dermatitis Eczema Eczema Atopic Eczema antimicrobial resistance zabalafin

Location: Annapolis, MD · source · May 20, 2024

Profile checked Oct 10, 2026

1Trials (company is sponsor)1NIH grants

Funding and NIH signals

NIH award NIH awarded $1.1M (SBIR Phase II 1R44AT013899-01, new, notice Sep 16, 2026). NIH RePORTER 1R44AT013899-01 (Sep 16, 2026)
Evidence (1 event)
- Sep 16, 2026 · NIH RePORTER 1R44AT013899-01
  Organization: ALPHYN BIOLOGICS, INC.; City/State: ANNAPOLIS, MD; Project number: 1R44AT013899-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1100000; Administering IC: National Center for Complementary and Integrative Health; Project title: AB-101: A Multi-Target Botanical Hydrogel for Combating Antimicrobial Resistance in Atopic Dermatitis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series B · $25M · announced Dec 12, 2025 Company release ↗
Source quote
- Dec 12, 2025 · Company release ↗
  “Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline”

Raises announced in these releases: $25M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Dec 12, 2025 Raise Series B · $25M source ↗
Mar 25, 2025 Trial start 2: Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06855745	Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.	2	Recruiting	Mar 25, 2025	Oct 30, 2025 (estimated)

NIH awards 1

Annual award amounts. Total $1.1M.

Sep 16, 2026 NIH award 1R44AT013899-01 FY2026: $1,100,000 awarded for that fiscal year; activity R44 (SBIR); PI PEKOE, GARY; recipient as written: ALPHYN BIOLOGICS, INC., ANNAPOLIS, MD. AB-101: A Multi-Target Botanical Hydrogel f source ↗